SCHEMBL3452137

SCHEMBL3452137

Cc1ccc(-c2cccc(CO)c2)c(C)c1

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAP2K4 P45985 1/20 0.51
FFAR1 O14842 2/20 0.51
PRKCI P41743 1/20 0.46
HTR7 P34969 2/20 0.45
ESR2 Q92731 2/20 0.44
PPARG P37231 1/20 0.40
PPARA Q07869 1/20 0.40
FYN P06241 1/20 0.40
ACMSD Q8TDX5 1/20 0.40
CHRNB4 P30926 1/20 0.40
CHRNA3 P32297 1/20 0.40
CHRNA7 P36544 1/20 0.40
LRRK2 Q5S007 1/20 0.39
CDK8 P49336 1/20 0.39
PTGER4 P35408 2/20 0.39
ESR1 P03372 1/20 0.39
CALML3 P27482 1/20 0.38
ENPP2 Q13822 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16057815 0.86 ESR2 (0.44) MAP2K4FFAR1PRKCIHTR7ESR2
SCHEMBL15229777 0.85 ESR2 (0.66) FFAR1PRKCIHTR7ESR2ACMSD
SCHEMBL16726970 0.83 PRKCI (0.44) MAP2K4FFAR1PRKCIHTR7ESR2
SCHEMBL2023225 0.83 FFAR1 (0.47) MAP2K4FFAR1PRKCIHTR7ESR2
SCHEMBL10981826 0.82 HTR7 (0.65) MAP2K4FFAR1PRKCIHTR7
SCHEMBL30196173 0.81 ESR2 (0.47) FFAR1HTR7ESR2ESR1
SCHEMBL16675748 0.81 FFAR1 (0.53) FFAR1PRKCIPPARGPPARAFYN
SCHEMBL20530624 0.81 MAP2K4 (0.47) MAP2K4FFAR1PRKCIHTR7FYN
SCHEMBL16745261 0.80 MAP2K4 (0.49) MAP2K4PRKCIHTR7FYNACMSD
SCHEMBL21670718 0.80 FFAR1 (0.46) MAP2K4FFAR1HTR7ESR2PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7820837-B2 ethyl {6-[(3-phenoxybenzyl)oxy]-3,4-dihydronaphthalen-1-yl}acetate; having a GPR40 receptor function modulating action and being useful as an insulin secretagogue or a pharmaceutical agent for the prophylaxis or treatment of diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-10-26 US disclosed
US-7820837-B2 ethyl {6-[(3-phenoxybenzyl)oxy]-3,4-dihydronaphthalen-1-yl}acetate; having a GPR40 receptor function modulating action and being useful as an insulin secretagogue or a pharmaceutical agent for the prophylaxis or treatment of diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-10-26 US disclosed
US-7820837-B2 ethyl {6-[(3-phenoxybenzyl)oxy]-3,4-dihydronaphthalen-1-yl}acetate; having a GPR40 receptor function modulating action and being useful as an insulin secretagogue or a pharmaceutical agent for the prophylaxis or treatment of diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-10-26 US disclosed
US-7456218-B2 3-(4-benzyloxyphenyl) propanoic acid derivatives TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-11-25 US disclosed
US-7456218-B2 3-(4-benzyloxyphenyl) propanoic acid derivatives TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-11-25 US disclosed
US-7456218-B2 3-(4-benzyloxyphenyl) propanoic acid derivatives TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-11-25 US disclosed
US-20070149608-A1 3-(4-Benzyloxyphenyl) propanoic acid derivatives TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-06-28 US disclosed
US-20070149608-A1 3-(4-Benzyloxyphenyl) propanoic acid derivatives TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-06-28 US disclosed
US-20070149608-A1 3-(4-Benzyloxyphenyl) propanoic acid derivatives TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-06-28 US disclosed
US-20060258722-A1 Condensed ring compound TAKEDA PHARMACEUTICAL COMPANY., LTD. (JP) 2006-11-16 US disclosed
EP-1630152-A1 CONDENSED RING COMPOUND Takeda Pharmaceutical Company Limited (JP) 2006-03-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070149608-A1 3-(4-Benzyloxyphenyl) propanoic acid derivatives GPR119, GPR55, GLP1R MAP2K4 3433/4885FFAR1 5/4885PRKCI 2010/4885
US-20060258722-A1 Condensed ring compound GPR119, GLP1R, GCGR MAP2K4 735/4885FFAR1 93/4885PRKCI 4633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.